Stoke Therapeutics Inc (STOK) financials
Stoke Therapeutics revenue and earnings by year
Stoke Therapeutics's revenue was $184 million in the fiscal year to December 31, 2025, up 404.5% from the year before. Net income was -$6.88 million, -3.7% of revenue. Since the fiscal year to December 31, 2022, revenue has grown 145.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 4 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 184 | 37 | 9 | 12 |
| Revenue growth | 404.5% | 316.3% | -29.2% | — |
| Operating income | -21 | -101 | -115 | -104 |
| Operating margin | -11.2% | -277.3% | -1307.2% | -841.2% |
| Net income | -7 | -89 | -105 | -101 |
| Net margin | -3.7% | -243.4% | -1192.5% | -814.7% |
| Diluted EPS | -$0.12 | -$1.65 | -$2.38 | -$2.60 |
| Free cash flow | 45 | -87 | -83 | -36 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open STOK in Markets.
See also: STOK returns
No forecast, no recommendation. This page describes Stoke Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.